Multicenter comparative analysis of FRED-X, pipeline shield, and surpass evolve in treating intracranial aneurysms.

Publication/Presentation Date

10-25-2025

Abstract

BackgroundIn recent years, newer flow diverters have been developed with surface modification and varying wire densities. Our study evaluated outcomes among three newer generation flow diverter devices, FRED-X, PED Shield and Surpass Evolve.MethodsThis was a retrospective study of patients from five participating institutions across the United States. Patients who underwent flow diversion of intracranial aneurysms using the FRED-X, PED Shield or Surpass Evolve between February 2022 and September 2024 were included. Outcomes of interest were technical success, angiographic occlusion and in-stent stenosis (ISS).ResultsAmong 447 patients with 452 aneurysms, adjunct device use was highest with Surpass Evolve (36.4%) versus PED Shield (15.7%) and FRED-X (6.4%) (

First Page

15910199251384687

Last Page

15910199251384687

ISSN

2385-2011

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

41137638

Department(s)

Administration and Leadership

Document Type

Article

Share

COinS